"Cardiac biomarker diagnostic kits market to exhibit dynamic growth during the forecast period"

The global cardiac biomarker diagnostic kits market is growing competently, expected to grow at a CAGR of 5.3%. Globally, the rising prevalence of chronic diseases, cardiac disorders along with numerous lifestyle diseases will drive the market growth globally. Major factors such as growing elderly population, increasing hospital admissions for cardiovascular diseases and enhanced product penetration in the developing nations are driving the global market. Present clinical trials for identification of innovative cardiac biomarkers, public and private funding for improved R&D is also increasing the market growth on a global scale. Globally, a gradual shift towards overall treatment along with diagnosis for various lifestyle and chronic diseases is one of the key factors driving the overall growth of the market. 

"Troponin test kits expected to register higher growth by the end of 2027" 

The troponin diagnostic test kits estimated to grow significantly during the forecast period, generated maximum revenue in 2018, and estimated to dominate by 2027. Top manufacturers are receiving the U.S. FDA clearance. Product penetration of this segment can be accredited to an increase in the demand for high sensitive troponin assay applications. For e.g. Alere recently launched next generation products such as Troponin I, Cardio2 and Cardio3. Prevalence of acute myocardial infarction (AMI) will boost the need for advanced diagnostic kits on a global scale. Additionally, huge number of pipeline products along with advancement in point-of-care (POC) cardiac testing will increasing the market share of diagnostic kits during the forecast period.

"Angina Pectoris segment to witness a significant CAGR"

Increasing prevalence of cardiovascular diseases, and growing number of adult population with increased incidence rate of stroke, diseases in the arteries, and other lifestyle diseases will upsurge the market demand for diagnostic kits. As per the statistics by American Heart Association, cardiovascular disease is the leading global cause of death, accounting for more than 17 Mn deaths per year globally, expected to grow to more than 23 million by 2030 worldwide. Additionally, more than 9 million people in the U.S are projected to experience angina pectoris every year, with more than 500,000 new cases of angina pectoris occurring annually. Increasing prevalence of these diseases along with new launch of products for various disease indications globally will further revenue growth during the forecast period. In 2014-2015, stroke and CVD accounted for around 14% of total health expenditures, more than any major diagnostic segment globally. The total direct and indirect costs were more than US$ 350 Bn. 

"Increased research and development with strong product pipelines in the developed regions"

Major manufacturers such as Abbott, Roche, Danaher and others are developing novel products with enhanced applications in the point of care and laboratory testing segment. Increasing demand for laboratory investigation for the identification and diagnostic testing of various cardiac diseases is driving the market growth. Novel diagnostic kit launch with higher compatibility, strategic collaborations, and innovative technology assessment in the emerging countries and improved clinical outcomes in the field of overall cardiac testing globally will further spur revenue growth on a global scale. For e.g. In March 2017, Fujirebio Europe (leader in IVD testing) launched Lumipulse G Myoglobin immunoassays and Lumipulse® G hs Troponin I for both LUMIPULSE G600II and G1200 platforms. 

Key Industry Developments: 

• In Oct 2017, Abbott Laboratories completed its acquisition of Alere (leader in rapid point-of-care diagnostics), closing a deal first declared in Feb 2016. 
• In September 2018, Celemics Inc. and Firalis S.A. launched FiMICS® panel. Both declared a definitive agreement for the commercialization of an exclusive proprietary long non-coding RNA (lncRNA) panel. 

Top Companies

• bioMerieux SA
• Danaher Corporation
• Guangzhou Wondfo Biotech Co., Ltd
• Siemens AG
• Abbott Laboratories
• Alere, Inc.
• LSI Medience Corporation
• Randox laboratories
• Ortho Clinical Diagnostics
• Hoffmann-La Roche AG
• Thermofisher Scientific
• Bio-Rad Laboratories
• Others 

Historical & Forecast Period 

This study report represents analysis for each segment from 2017 to 2027 considering 2018 to be the base year. Compounded Annual Growth Rate (CAGR) for each of the respective segments estimated for the forecast period from 2019 to 2027. 

Market Segmentation

The current report also comprehends qualitative and qualitative market valuation factors such as key market drivers, market trends, restraints and opportunities that gives a better market understanding of the overall cardiac biomarker diagnostic kits market. Additionally, the global report also comprises graphical representation of competitive landscape based on their market initiatives and strategies, product portfolio and business strengths.

Key questions answered in this report 

• What are the current market trends and dynamics in the cardiac biomarker diagnostic kits market and valuable opportunities for emerging players?
• Which segment accounts for the fastest CAGR during the forecast period and why?
• Which product type segment holds a larger market share and why?
• Are low and middle-income economies investing in the cardiac biomarker diagnostic kits market?
• What is the market trend and dynamics in emerging markets such as Asia Pacific, Latin America and Middle East & Africa?

TABLE 1 Market Snapshot: Global Cardiac Biomarker Diagnostic Kits (CBDK) Market
TABLE 2 Impact Indicators
TABLE 3 Impact Analysis of Drivers and Restraints
TABLE 4 Global CBDK Market, by Product Type, 2017–2027 (US$ Mn)
TABLE 5 Global CBDK Market, Disease Indication, 2017–2027 (US$ Mn)
TABLE 6 Global CBDK Market, by Testing, 2017–2027 (US$ Mn)
TABLE 7 Global CBDK Market, by Geography, 2017–2027 (US$ Mn)
TABLE 8 North America CBDK Market, by Product Type, 2017–2027 (US$ Mn)
TABLE 9 North America CBDK Market, Disease Indication, 2017–2027 (US$ Mn)
TABLE 10 North America CBDK Market, by Testing, 2017–2027 (US$ Mn)
TABLE 11 North America CBDK Market, by Country, 2017–2027 (US$ Mn)
TABLE 12 Europe CBDK Market, by Product Type, 2017–2027 (US$ Mn)
TABLE 13 Europe CBDK Market, Disease Indication, 2017–2027 (US$ Mn)
TABLE 14 Europe CBDK Market, by Testing, 2017–2027 (US$ Mn)
TABLE 15 Europe CBDK Market, by Country/Region, 2017–2027 (US$ Mn)
TABLE 16 Asia Pacific CBDK Market, by Product Type, 2017–2027 (US$ Mn)
TABLE 17 Asia Pacific CBDK Market, Disease Indication, 2017–2027 (US$ Mn)
TABLE 18 Asia Pacific CBDK Market, by Testing, 2017–2027 (US$ Mn)
TABLE 19 Asia Pacific CBDK Market, by Country/Region, 2017–2027 (US$ Mn)
TABLE 20 Rest of the World CBDK Market, by Product Type, 2017–2027 (US$ Mn)
TABLE 21 Rest of the World CBDK Market, Disease Indication, 2017–2027 (US$ Mn)
TABLE 22 Rest of the World CBDK Market, by Testing, 2017–2027 (US$ Mn)
TABLE 23 Rest of the World CBDK Market, by Region, 2017–2027 (US$ Mn)
TABLE 24 bioMerieux SA: Company Snapshot (Company Overview; Product Portfolio; Financial Information; Key Developments)
TABLE 25 Danaher Corporation: Company Snapshot (Company Overview; Product Portfolio; Financial Information; Key Developments)
TABLE 26 Guangzhou Wondfo Biotech Co., Ltd: Company Snapshot (Company Overview; Product Portfolio; Financial Information; Key Developments)
TABLE 27 Siemens AG: Company Snapshot (Company Overview; Product Portfolio; Financial Information; Key Developments)
TABLE 28 Abbott Laboratories: Company Snapshot (Company Overview; Product Portfolio; Financial Information; Key Developments)
TABLE 29 Alere, Inc..: Company Snapshot (Company Overview; Product Portfolio; Financial Information; Key Developments)
TABLE 30 LSI Medience Corporation: Company Snapshot (Company Overview; Product Portfolio; Financial Information; Key Developments)
TABLE 31 Randox laboratories: Company Snapshot (Company Overview; Product Portfolio; Financial Information; Key Developments)
TABLE 32 Ortho Clinical Diagnostics: Company Snapshot (Company Overview; Product Portfolio; Financial Information; Key Developments)
TABLE 33 Hoffmann-La Roche AG: Company Snapshot (Company Overview; Product Portfolio; Financial Information; Key Developments)
TABLE 34 Bio-Rad Laboratories: Company Snapshot (Company Overview; Product Portfolio; Financial Information; Key Developments)
TABLE 35 Thermofisher Scientific: Company Snapshot (Company Overview; Product Portfolio; Financial Information; Key Developments)